Cargando…
Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some pa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878174/ https://www.ncbi.nlm.nih.gov/pubmed/36477621 http://dx.doi.org/10.1111/bjh.18591 |
_version_ | 1784878445063307264 |
---|---|
author | Spyridonidis, Alexandros |
author_facet | Spyridonidis, Alexandros |
author_sort | Spyridonidis, Alexandros |
collection | PubMed |
description | When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some patients to establish an adequate humoral response. Commentary on: Bankova et al. Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic hematopoietic cell transplantation. Br J Haematol. 2022 (Online ahead of print). doi: 10.1111/bjh.18562. xxx |
format | Online Article Text |
id | pubmed-9878174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98781742023-01-26 Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? Spyridonidis, Alexandros Br J Haematol Commentary When and how often should allogeneic haematopoietic cell transplantation recipients be vaccinated against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is unclear. The report by Bankova et al. suggests that a third SARS‐CoV‐2 vaccine dose is important but still insufficient in some patients to establish an adequate humoral response. Commentary on: Bankova et al. Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic hematopoietic cell transplantation. Br J Haematol. 2022 (Online ahead of print). doi: 10.1111/bjh.18562. xxx John Wiley and Sons Inc. 2022-12-07 /pmc/articles/PMC9878174/ /pubmed/36477621 http://dx.doi.org/10.1111/bjh.18591 Text en © 2022 The Author. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Commentary Spyridonidis, Alexandros Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title | Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title_full | Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title_fullStr | Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title_full_unstemmed | Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title_short | Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
title_sort | is a third sars‐cov‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878174/ https://www.ncbi.nlm.nih.gov/pubmed/36477621 http://dx.doi.org/10.1111/bjh.18591 |
work_keys_str_mv | AT spyridonidisalexandros isathirdsarscov2vaccinedoseefficientinallogeneichaematopoieticcelltransplantrecipients |